

BACK TO

BASICS PNEUMONIA

BASICS: Usual Suspects

S.pneumoniae

H.influenzae

Legionella sp.

Viruses (At least 20% of cases)

BASICS: Signs & Symptoms

- **⊘** Chills
- Shortness of breath

AND

Positive radiographic findings (chest x-ray/CT scan)

BASICS: Diagnostic Imaging

- - Ø Gold standard for diagnostic imaging

Significant findings

BASICS: Clinical Conundrums

	Commonalities	Differences
Asthma exacerbation	Cough Wheeze	No radiographic changes
Bronchitis	Cough Wheeze Fever	No radiographic changes
Heart Failure	Shortness of breath Cough	CXR – Pulmonary venous congestion, interstitial edema, perihilar infiltrates, enlarged cardiac silhouette, effusions (Clinically: Orthopnea, PND)
Pulmonary Embolism	Fever Leukocytosis Shortness of breath Hemoptysis	CT – Clot(s) evident on CT (usually presents with parenchymal changes, e.g. airspace opacities/ground glass)
Lung disease (ILD,IPF)	Shortness of breath Cough Wheeze	CXR/CT – Various interstitial findings/chronic changes (e.g. Septal thickening, honeycombing, bronchiectasis) (Clinically: Unlike CAP, onset is gradual but can exacerbate)

BASICS: In-Patient Treatment Options

Non-ICU patients

First line

- Amoxicillin-clavulanate
 OR Cefuroxime
- Ceftriaxone

Anaphylaxis to beta-lactams

Levofloxacin 750mg

ICU patients

First line

Ceftriaxone + Azithromycin IV/PO 500mg

Anaphylaxis to beta-lactams

Levofloxacin 750mg

PO Step down

- ✓ Able to take PO meds
- ✓ Afebrile for 24-48 hours

BASICS: In-Patient Treatment Options

What's with ASP's obsession with amoxicillin-clavulanate?

Spectrum

Covers all typical CAP pathogens (except atypicals!)

Safety profile

Favourable compared to fluoroquinolones

Frequency

875 mg/125 mg PO BID (reduced clavulanate component)

What about Cefuroxime?

Reasonable alternative

Growing concern with resistance?

H. influenzae - 18-22%

S. pneumoniae – 12%

BASICS: Common Problems

- Empiric *Pseudomonas* coverage is **inappropriate**
 - Healthcare-associated (HCAP) & Nursing-home associated (NAP) pneumonia are dead
 - Not relevant in overwhelming majority of community cases
 - Therapy should be switched to guideline driven agents (Clavulin, or ceftriaxone)
- Beta-lactam + Fluoroquinolone combination is inappropriate
 - Significant overlap in spectrum
 - Poor evidence/justification for inclusion in old (2007) CAP guidelines for ICU patients
 - Discontinue fluoroquinolone, continue beta-lactam monotherapy
- Zpak dosing is problematic
 - Doses of 250 mg too low for Legionella (which is it's ONLY role in CAP)
 - Discontinue, or if Legionella is a serious consideration, increase to 500 mg daily

BASICS: Treatment Duration

Guidelines: 5-7 days

Treatment Discontinuation(non-ICU)

Minimum of 5 days, afebrile (<37.8) x 48 hours

PLUS

No more than **one** sign of instability

- SBP < 90 mmHg
- HR > 100/min
- RR > 24 /min
- O2 sat < 90% / PaO2 < 60mmHg on room air

NOT BASIC: Legionella Pneumonia

- Uncommon (but becoming more common)
- "Severe pneumonia"
 - ICU admission (75% of cases)
- Increased incidence in summer months
 - Hot & humid weather (i.e. May-October)
- Presentation
 - ?GI symptoms
 - ?Hepatic insult (increased LFTs)
 - ?Elevated CK

- ?Hyponatremia
- ?Altered LOC
- ?Elevated SCr
- Urine Legionella Detects urinary antigen of *L. pneumophila* serotype 1
 - Responsible for majority (80%) of cases

NOT BASIC: Legionella Pneumonia

Treatment

Consider adding azithromycin IV/PO 500 mg daily if:

- Critically ill (i.e. ICU admission)
- Continued deterioration despite 48h-72h of standard therapy (i.e. beta-lactam)

In **confirmed** *Legionella* pneumonia

Monotherapy with fluoroquinolone (i.e. Levofloxacin) or macrolides (i.e. azithromycin)

Duration

- 7-10 days
- Longer (i.e. 14-21 days) in severe disease or immunocompromised patients



BACK TO

BASICS Patient Cases

CASE 1 - EF (75/F)

EF - 75 yo F

Presentation:

Ø Fever (39.3) and productive cough, requiring 2 L O2 via nasal prongs

Diagnostic Imaging

NKDA

Initial antibiotics:

- Ø Ceftriaxone 1 g IV daily
- Azithromycin 500 mg PO daily then 250 mg PO x 4 days

Review (Day 3)

CASE 2 – JP (62/M)

JP - 62 yo M

Presentation:

Diagnostic Imaging

CXR: Left middle lobe consolidation

NKDA

Initial antibiotics:

Review (Day 4)

- Ø Satting 98% on room air

CASE 3 – TW (64/F)

TW - 64 yo F

Presentation:

2-week history of worsening shortness of breath (especially on exertion), pedal edema, requiring 2-3 pillows to sleep

Diagnostic Imaging

PMHx: Atrial fibrillation, hypertension, dyslipidemia

NKDA

Initial antibiotics:

 Ø Ceftriaxone 1 g IV daily

Review (Day 2)

- Ø Satting 95% on 3L NP

BASICS: Quick Tips

Quick References

Overall

Ontario Quality Based Practices (QBP) for Pneumonia

Duration

JAMA Intern Med. 2016;176(9):1257-1265

Avoidance of FQs

FDA Warning (July 26th 2016)